THE VALUE OF ADJUVANT RADIOTHERAPY IN PULMONARY AND CHEST WALL RESECTION FOR BRONCHOGENIC-CARCINOMA
THE VALUE OF ADJUVANT RADIOTHERAPY IN PULMONARY AND CHEST WALL RESECTION FOR BRONCHOGENIC-CARCINOMA
复制标题
DOI：
10.1016/s0003-4975(10)60911-3
复制
发表时间：
1982-01-01
影响因子：
4.6
通讯作者：
PEARSON, FG
中科院分区：
文献类型：
--
作者：
PATTERSON, GA;ILVES, R;PEARSON, FG
35例患者，29名男性和6名女性，接受了肺和胸壁切除术治疗已扩展到胸壁的支气管肺癌。前胸壁切除6例，侧胸壁切除2例，后胸壁切除27例。13例患者使用Marlex补片作为假体材料。放射治疗作为计划的治疗方案的一部分，在13例患者。术后死亡3例（8.5%）。有21人死亡。11例存活7个月。术后12年。总的精算生存率，包括手术死亡率，是38%，在5年。13例放射治疗患者的2年和5年生存率为56%。支气管肺癌累及胸壁并非没有希望，肺和胸壁切除术的死亡率可以接受。
Thrity-five patients, 29 men and 6 women, underwent pulmonary and chest wall resection for treatment of bronchogenic cancer which had extended into the chest wall. Anterior chest wall resection was performed in 6 patients, lateral resection in 2 and posterior resection in 27. Marlex mesh was employed as a prosthetic material in 13 patients. Radiotherapy was given as part of the planned therapeutic regime in 13 patients. Three patients (8.5%) died in the postoperative period. There were 21 late deaths. Eleven patients were alive 7 mo. to 12 yr after resection. The overall actuarial survival, including operative mortality, is 38% at 5 yr. Actuarial survival of the 13 irradiated patients is 56% at 2 and 5 yr. Bronchogenic carcinoma with chest wall involvement is not hopeless; resection of the lung and chest wall can be performed with an acceptable mortality rate.